Management of Rivaroxaban-Associated Epistaxis

Initial Assessment and Classification

The American College of Cardiology recommends determining bleeding severity immediately, with non-major epistaxis characterized by no hemodynamic instability, hemoglobin drop <2 g/dL, no transfusion needed, and not at a critical site 1
Major epistaxis is defined as hemodynamic instability, hemoglobin decrease ≥2 g/dL, administration of ≥2 units RBCs, or bleeding at a critical site 1, 4

The American Academy of Otolaryngology-Head and Neck Surgery suggests continuing rivaroxaban and applying local measures, including firm sustained compression to the lower third of the nose for 5-15 minutes 1, 2, 3, 5, 6
After compression, cleaning the nasal cavity of clots and applying topical vasoconstrictors (oxymetazoline or phenylephrine) can stop bleeding in 65-75% of cases 7
If bleeding persists, performing anterior rhinoscopy to identify the bleeding site after clot removal is recommended 2, 6
Treating the identified bleeding site with nasal cautery (after anesthetizing the site) or moisturizing/lubricating agents is also recommended 2, 6

The American College of Cardiology recommends stopping rivaroxaban immediately and providing local therapy/manual compression 1, 4
Providing supportive care and volume resuscitation is also crucial 1
Considering reversal agents, such as andexanet alfa, if bleeding is at a critical site or life-threatening is recommended 1, 4, 8
Activated charcoal can be used if rivaroxaban was taken within the previous 2 hours 8

The American College of Cardiology notes that rivaroxaban half-life varies by renal function, with a half-life of 6-9 hours in patients with normal renal function (CrCl ≥80 mL/min) 4
In patients with moderate impairment (CrCl 30-49 mL/min), the half-life is 9 hours, and in those with severe impairment (CrCl 15-29 mL/min), it is 13 hours (off dialysis) 4

The American College of Cardiology recommends assessing the patient's condition before restarting rivaroxaban, considering factors such as the site of bleeding, risk of rebleeding, and planned surgical procedures 1
Restarting rivaroxaban 24 hours after hemostasis is achieved is recommended for patients with low bleeding risk, while those with high bleeding risk should wait 48-72 hours 8, 9

The American College of Cardiology advises against routinely stopping rivaroxaban for minor epistaxis, as this increases thrombotic risk without improving outcomes 1, 2, 3
Using reversal agents for non-major bleeding is also not recommended, as local control is sufficient and reversal carries thrombotic risks 1, 2

The American Academy of Otolaryngology-Head and Neck Surgery recommends educating patients on avoiding straining, lifting, bending, and exercising during active bleeding, and using acetaminophen for pain instead of aspirin or ibuprofen 5
Patients should also be instructed to apply nasal saline sprays regularly to keep the mucosa moist and seek immediate care if bleeding persists or if fever, vision changes, or facial swelling develop 5, 7